Close Menu

NEW YORK (GenomeWeb) – Cervical cancer screening using human papillomavirus (HPV) testing leads to significantly fewer high-grade cervical pathologies four years later than standard liquid-based cytology (LBC) screening, according to a randomized trial of approximately 19,000 Canadian women.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.